

|  |
| --- |
| Victorian Radiotherapy Minimum Dataset user manual 2023-24 |
| Version 3.43  |
| OFFICIAL |

|  |
| --- |
|  |
|  |
| To receive this document in another format, phone +61 3 9456 4036, using the National Relay Service 13 36 77 if required, or email the Cancer Services & Information Unit <Radiotherapy.VRMDS@health.vic.gov.au>Authorised and published by the Victorian Government, 1 Treasury Place, Melbourne.© State of Victoria, Australia, Department of Health, June 2023**ISBN** 978-1-76131-173-4 **(pdf/online/MS word)**Available from [the department's radiotherapy web page](https://www.health.vic.gov.au/publications/victorian-radiotherapy-minimum-data-set-user-manual-and-appendices) <https://www.health.vic.gov.au/publications/victorian-radiotherapy-minimum-data-set-user-manual-and-appendices> |
|  |

Contents

[Section 1: Introduction 7](#_Toc135922933)

[VRMDS: background and purpose 7](#_Toc135922934)

[VRMDS user manual 7](#_Toc135922935)

[Purpose 7](#_Toc135922936)

[Contact 7](#_Toc135922937)

[Relevant references 7](#_Toc135922938)

[VRMDS data submission dates 8](#_Toc135922939)

[Section 2: Data items and definitions 9](#_Toc135922940)

[Data summary table and changes 9](#_Toc135922941)

[Group A patient demographic data items 14](#_Toc135922942)

[1 Patient First Name 14](#_Toc135922943)

[2 Patient Surname (Family Name) 14](#_Toc135922944)

[3 Patient Street Address 15](#_Toc135922945)

[4 Patient Locality 15](#_Toc135922946)

[5 Patient Postcode of Residence 16](#_Toc135922947)

[6 Date of Birth 16](#_Toc135922948)

[7 Sex 17](#_Toc135922949)

[8 Medicare Number 17](#_Toc135922950)

[9 Indigenous Status 18](#_Toc135922951)

[Group B Service data items 19](#_Toc135922952)

[10 Hospital Name 19](#_Toc135922953)

[11 Hospital Code 19](#_Toc135922954)

[12 Campus Name 20](#_Toc135922955)

[13 Campus Code 20](#_Toc135922956)

[14 Unit Record Number 21](#_Toc135922957)

[15 Account Class 22](#_Toc135922958)

[16 Course Id 23](#_Toc135922959)

[17 Primary Site of Cancer 23](#_Toc135922960)

[17a Primary Site of Cancer 2 24](#_Toc135922961)

[18 Treating Doctor First Name 25](#_Toc135922962)

[19 Treating Doctor Surname (Family Name) 25](#_Toc135922963)

[20 Date of 1st Consultation with Radiation Oncologist 26](#_Toc135922964)

[21 Radiotherapy Date Ready for Care 26](#_Toc135922965)

[22 Radiotherapy Treatment Start Date 27](#_Toc135922966)

[23 Radiotherapy Treatment Completion Date 27](#_Toc135922967)

[24 New Treatment / Retreatment 28](#_Toc135922968)

[25 Intention of Radiotherapy Treatment 28](#_Toc135922969)

[26 Simulation 1 29](#_Toc135922970)

[27 Simulation 2 30](#_Toc135922971)

[28 Simulation 3 31](#_Toc135922972)

[29 Dosimetry 1 31](#_Toc135922973)

[30 Dosimetry 2 32](#_Toc135922974)

[31 Dosimetry 3 33](#_Toc135922975)

[32 Treatment Modality 34](#_Toc135922976)

[33 Total Radiation Fractions 34](#_Toc135922977)

[34 Total Number of Fields 35](#_Toc135922978)

[35 Inpatient Fractions 36](#_Toc135922979)

[36 Inpatient Fields 36](#_Toc135922980)

[37 Target Site of Radiotherapy 1 37](#_Toc135922981)

[38 Prescribed Dose for Target Site 1 37](#_Toc135922982)

[39 Delivered Dose for Target Site 1 38](#_Toc135922983)

[40 Total Fractions for Target Site 1 38](#_Toc135922984)

[41 Treatment Technique for Target Site 1 40](#_Toc135922985)

[42 Total Fields for Target Site 1 41](#_Toc135922986)

[43 Target Site of Radiotherapy 2 42](#_Toc135922987)

[44 Prescribed Dose for Target Site 2 42](#_Toc135922988)

[45 Delivered Dose for Target Site 2 43](#_Toc135922989)

[46 Total Fractions for Target Site 2 43](#_Toc135922990)

[47 Treatment Technique for Target Site 2 44](#_Toc135922991)

[48 Total Fields for Target Site 2 44](#_Toc135922992)

[49 Target Site of Radiotherapy 3 45](#_Toc135922993)

[50 Prescribed Dose for Target Site 3 46](#_Toc135922994)

[51 Delivered Dose for Target Site 3 46](#_Toc135922995)

[52 Total Fractions for Target Site 3 47](#_Toc135922996)

[53 Treatment Technique for Target Site 3 48](#_Toc135922997)

[54 Total Fields for Target Site 3 49](#_Toc135922998)

[55 Target Site of Radiotherapy 4 49](#_Toc135922999)

[56 Prescribed Dose for Target Site 4 50](#_Toc135923000)

[57 Delivered Dose for Target Site 4 50](#_Toc135923001)

[58 Total Fractions for Target Site 4 51](#_Toc135923002)

[59 Treatment Technique for Target Site 4 52](#_Toc135923003)

[60 Total Fields for Target Site 4 53](#_Toc135923004)

[61 Target Site of Radiotherapy 5 53](#_Toc135923005)

[62 Prescribed Dose for Target Site 5 54](#_Toc135923006)

[63 Delivered Dose for Target Site 5 54](#_Toc135923007)

[64 Total Fractions for Target Site 5 55](#_Toc135923008)

[65 Treatment Technique for Target Site 5 56](#_Toc135923009)

[66 Total Fields for Target Site 5 57](#_Toc135923010)

[67 Target Site of Radiotherapy 6 57](#_Toc135923011)

[68 Prescribed Dose for Target Site 6 58](#_Toc135923012)

[69 Delivered Dose for Target Site 6 58](#_Toc135923013)

[70 Total Fractions for Target Site 6 59](#_Toc135923014)

[71 Treatment Technique for Target Site 6 60](#_Toc135923015)

[72 Total Fields for Target Site 6 61](#_Toc135923016)

[73 Target Site of Radiotherapy 7 61](#_Toc135923017)

[74 Prescribed Dose for Target Site 7 62](#_Toc135923018)

[75 Delivered Dose for Target Site 7 62](#_Toc135923019)

[76 Total Fractions for Target Site 7 63](#_Toc135923020)

[77 Treatment Technique for Target Site 7 64](#_Toc135923021)

[78 Total Fields for Target Site 7 65](#_Toc135923022)

[79 Target Site of Radiotherapy 8 65](#_Toc135923023)

[80 Prescribed Dose for Target Site 8 66](#_Toc135923024)

[81 Delivered Dose for Target Site 8 66](#_Toc135923025)

[82 Total Fractions for Target Site 8 67](#_Toc135923026)

[83 Treatment Technique for Target Site 8 68](#_Toc135923027)

[84 Total Fields for Target Site 8 69](#_Toc135923028)

[85 Target Site of Radiotherapy 9 69](#_Toc135923029)

[86 Prescribed Dose for Target Site 9 70](#_Toc135923030)

[87 Delivered Dose for Target Site 9 70](#_Toc135923031)

[88 Total Fractions for Target Site 9 71](#_Toc135923032)

[89 Treatment Technique for Target Site 9 72](#_Toc135923033)

[90 Total Fields for Target Site 9 73](#_Toc135923034)

[91 Target Site of Radiotherapy 10 73](#_Toc135923035)

[92 Prescribed Dose for Target Site 10 74](#_Toc135923036)

[93 Delivered Dose for Target Site 10 74](#_Toc135923037)

[94 Total Fractions for Target Site 10 75](#_Toc135923038)

[95 Treatment Technique for Target Site 10 76](#_Toc135923039)

[96 Total Fields for Target Site 10 77](#_Toc135923040)

[97 Number of Treatment Reviews 77](#_Toc135923041)

[98 IGRT 2D 78](#_Toc135923042)

[99 IGRT 3D 78](#_Toc135923043)

[Section 3: File format, data transfer procedures, privacy and confidentiality 79](#_Toc135923044)

[Section 4: Access to data 80](#_Toc135923045)

[Appendix 1: Hospital and campus name and code list 81](#_Toc135923046)

[Appendix 2: Course ID 83](#_Toc135923047)

[Appendix 2a: Kilovoltage (KVT) course description 84](#_Toc135923048)

[Appendix 3: Ready for care 85](#_Toc135923049)

[Appendix 4: Intention of radiotherapy treatment 87](#_Toc135923050)

[Definitions 87](#_Toc135923051)

[Appendix 5: Treatment technique 89](#_Toc135923052)

[Permissible codes and definitions of radiation therapy techniques for the Victorian Radiotherapy Minimum Dataset 89](#_Toc135923053)

[Appendix 6: Target site code list 94](#_Toc135923054)

# Section 1: Introduction

The Victorian Radiotherapy Minimum Data Set (VRMDS) contains demographic, administrative and clinical data for admitted and non-admitted patients treated in Victorian radiotherapy facilities in the public and private sector.

## VRMDS: background and purpose

The VRMDS began in 2008–09 as an initiative of the then Department of Health in collaboration with Victorian radiotherapy providers.

The purpose of the data collection is to provide the department with relevant data to inform service planning considerations for radiotherapy facilities, including metrics that inform this such as waiting times, and radiotherapy utilisation rates compared with optimal rates.

The department also collects a subset of data items on behalf of the Victorian Cancer Registry, under the auspices of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015.

## VRMDS user manual

### Purpose

The purpose of the VRMDS user manual is to provide contributors to, and users of, the VRMDS with a complete information resource on the dataset.

It is designed to:

* provide the necessary information to successfully compile and transmit the data files
* familiarise contributors and users with data items and edits
* detail or provide the location of related reference files and code lists
* identify support services and contact details.

### Contact

Telephone: 9456 4036

Email: Cancer Services & Information Unit <Radiotherapy.VRMDS@health.vic.gov.au>

## Relevant references

Table 1: Publications and websites

| VRMDS and other relevant reference files | Website URL |
| --- | --- |
| [Department of Health: Cancer](file:///C%3A%5CUsers%5Ckkar1405%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CINetCache%5CContent.Outlook%5CMA1M4LC2%5Cwww2.health.vic.gov.au%5Cabout%5Chealth-strategies%5Ccancer-care) | www2.health.vic.gov.au/about/health-strategies/cancer-care |
| [Department of Health: Hospital circulars](file:///C%3A%5CUsers%5Ckkar1405%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CINetCache%5CContent.Outlook%5CMA1M4LC2%5Cwww2.health.vic.gov.au%5Cabout%5Cnews-and-events%5Chospitalcirculars) | www2.health.vic.gov.au/about/news-and-events/hospitalcirculars |
| [Department of Health: Radiotherapy](https://www2.health.vic.gov.au/about/health-strategies/cancer-care/radio-therapy)  | https://www2.health.vic.gov.au/about/health-strategies/cancer-care/radio-therapy |
| [Postcode locality](https://www2.health.vic.gov.au/about/publications/researchandreports/postcode-locality-reference) | https://www2.health.vic.gov.au/about/publications/researchandreports/postcode-locality-reference  |
| [Victorian Cancer Registry](http://www.cancervic.org.au/research/registry-statistics/vcr) | www.cancervic.org.au/research/registry-statistics/vcr  |
| [Guide to identifying reportable cancers](http://www.cancervic.org.au/downloads/research/registry/Reportable-Cancers-Guide-to-identification-of-cancers-reportable-to-the-Victorian-Cancer-Registry-July-2018.pdf) | www.cancervic.org.au/downloads/research/registry/Reportable-Cancers-Guide-to-identification-of-cancers-reportable-to-the-Victorian-Cancer-Registry-July-2018.pdf |

## VRMDS data submission dates

VRMDS data must be submitted monthly, beginning on 30 August of each financial year. The submission will report courses completed in the previous month.

Table 2: VRMDS submission dates

| Submission date | Data period (courses completed) |
| --- | --- |
| 30 August | July |
| 30 September | August |
| 30 October | September |
| 30 November | October |
| 30 December | November |
| 30 January | December |
| 28 February | January |
| 30 March | February |
| 30 April | March |
| 30 May | April |
| 30 June | May |
| 30 July | June |

# Section 2: Data items and definitions

This section lists the data elements of the VRMDS and provides the definitions, formats, maximum field size, code sets and other information for each element.

The data items in the summary table below are grouped into patient demographic (Group A) and service/clinical (Group B) data items in the detailed specification tables that follow.

Items labelled ‘F’ are required for funding model purposes.

## Data summary table and changes

Table 3: Specifications

| Item no. | Data element name | Abbreviated name | Changes in V 3.43 |
| --- | --- | --- | --- |
| 1 | Patient First Name | PFirstName |  |
| 2 | Patient Surname (Family Name) | PSurname |  |
| 3 | Patient Street Address | PStreetAddr |  |
| 4 | Patient Locality | PLocality |  |
| 5 | Patient Postcode of Residence | PostcodeRes |  |
| 6 | Date of Birth | DoB |  |
| 7 | Sex | Sex |  |
| 8 | Medicare Number | MedicareNo |  |
| 9 | Indigenous Status | IndigStatus |  |
| 10 | Hospital Name | HosName |  |
| 11 | Hospital Code | HosCode |  |
| 12 | Campus Name | CampName | New campus added in Appendix 1 |
| 13 | Campus Code | CampCode | New campus added in Appendix 1 |
| 14 | Unit Record Number | URN |  |
| 15 | Account Class (F) | AccClass |  |
| 16 | Course Id | CourseId | Additional information |
| 17 | Primary Site of Cancer / ICD-10-AM | PrimarySite |  |
| 17a | Primary Site of Cancer 2/ ICD-10-AM | PrimarySite2 | New item (for conditional use) |
| 18 | Treating Doctor First Name | ROFirstName |  |
| 19 | Treating Doctor Surname (Family Name) | ROSurname |  |
| 20 | Date of 1st Consultation with Radiation Oncologist | 1stConsultRO |  |
| 21 | Radiotherapy Ready for Care Date | RFC |  |
| 22 | Radiotherapy Treatment Start Date | StartDate |  |
| 23 | Radiotherapy Course Completion Date | CompletionDate |  |
| 24 | New Treatment / Retreatment | NewTreat/Retreat |  |
| 25 | Intention of Radiotherapy Treatment | Intent |  |
| 26 | Simulation 1 \* (F) | Sim1 |  |
| 27 | Simulation 2 \* (F) | Sim2 |  |
| 28 | Simulation 3 \* (F) | Sim3 |  |
| 29 | Dosimetry 1 \* (F) | Dos1 |  |
| 30 | Dosimetry 2 \* (F) | Dos2 |  |
| 31 | Dosimetry 3 \* (F) | Dos3 |  |
| 32 | Treatment Modality (F) | Modality |  |
| ~~33~~ | ~~Treatment Technique (F)~~ | ~~Technique~~ |  |
| 33 | Total Radiation Fractions | TotalFractions | Amended. Effective 1 July 2023 |
| 34 | Total Number of Fields (F) | TotalFields |  |
| 35 | Inpatient Fractions | InpFractions |  |
| 36 | Inpatient Fields \* (F) | InpFields |  |
| 37 | Target Site of Radiotherapy 1 | TargetSite1 | New Target Sites added 18c,19c,20c,21c Effective from 1 July 2023 |
| 38 | Prescribed Dose for Target Site 1 | PrescrDose1 |  |
| 39 | Delivered Dose for Target Site 1 | DelivDose1 |  |
| 40 | Total Fractions for Target Site 1 | TFractionsTarget1 |  |
| 41 | Treatment Technique for Target Site 1 (F) | TechTarget1 | Code 7= Paediatric obsolete from 1 July 2023 |
| 42 | Total Fields for Target Site 1 | TFieldsTarget1 |  |
| 43 | Target Site of Radiotherapy 2 | TargetSite2 | New Target Sites added 18c,19c,20c,21c. Effective from 1 July 2023 |
| 44 | Prescribed Dose for Target Site 2 | PrescrDose2 |  |
| 45 | Delivered Dose for Target Site 2 | DelivDose2 |  |
| 46 | Total Fractions for Target Site 2 | TFractionsTarget2 |  |
| 47 | Treatment Technique for Target Site 2 (F) | TechTarget2 | Code 7= Paediatric obsolete from 1 July 2023 |
| 48 | Total Fields for Target Site 2 | TFieldsTarget2 |  |
| 49 | Target Site of Radiotherapy 3 | TargetSite3 | New Target Sites added 18c,19c,20c,21c Effective from 1 July 2023 |
| 50 | Prescribed Dose for Target Site 3 | PrescrDose3 |  |
| 51 | Delivered Dose for Target Site 3 | DelivDose3 |  |
| 52 | Total Fractions for Target Site 3 | TFractionsTarget3 |  |
| 53 | Treatment Technique for Target Site 3 (F) | TechTarget3 | Code 7= Paediatric obsolete from 1 July 2023 |
| 54 | Total Fields for Target Site 3 | TFieldsTarget3 |  |
| 55 | Target Site of Radiotherapy 4 | TargetSite4 | New Target Sites added 18c,19c,20c,21cEffective from 1 July 2023 |
| 56 | Prescribed Dose for Target Site 4 | PrescrDose4 |  |
| 57 | Delivered Dose for Target Site 4 | DelivDose4 |  |
| 58 | Total Fractions for Target Site 4 | TFractionsTarget4 |  |
| 59 | Treatment Technique for Target Site 4 (F) | TechTarget4 | Code 7= Paediatric obsolete from 1 July 2023 |
| 60 | Total Fields for Target Site 4 | TFieldsTarget4 |  |
| 61 | Target Site of Radiotherapy 5 | TargetSite5 | New Target Sites added 18c,19c,20c,21cEffective from 1 July 2023 |
| 62 | Prescribed Dose for Target Site 5 | PrescrDose5 |  |
| 63 | Delivered Dose for Target Site 5 | DelivDose5 |  |
| 64 | Total Fractions for Target Site 5 | TFractionsTarget5 |  |
| 65 | Treatment Technique for Target Site 5 (F) | TechTarget5 | Code 7= Paediatric obsolete from 1 July 2023 |
| 66 | Total Fields for Target Site 5 | TFieldsTarget5 |  |
| 67 | Target Site of Radiotherapy 6 | TargetSite6 | New Target Sites added 18c,19c,20c,21cEffective from 1 July 2023 |
| 68 | Prescribed Dose for Target Site 6 | PrescrDose6 |  |
| 69 | Delivered Dose for Target Site 6 | DelivDose6 |  |
| 70 | Total Fractions for Target Site 6 | TFractionsTarget6 |  |
| 71 | Treatment Technique for Target Site 6 (F) | TechTarget6 | Code 7= Paediatric obsolete from 1 July 2023 |
| 75 | Total Fields for Target Site 6 | TFieldsTarget6 |  |
| 73 | Target Site of Radiotherapy 7 | TargetSite7 |  |
| 74 | Prescribed Dose for Target Site 7 | PrescrDose7 |  |
| 75 | Delivered Dose for Target Site 7 | DelivDose7 |  |
| 76 | Total Fractions for Target Site 7 | TFractionsTarget7 |  |
| 77 | Treatment Technique for Target Site 7 (F) | TechTarget7 | Code 7= Paediatric obsolete from 1 July 2023 |
| 78 | Total Fields for Target Site 7 | TFieldsTarget7 |  |
| 79 | Target Site of Radiotherapy 8 | TargetSite8 | New Target Sites added 18c,19c,20c,21cEffective from 1 July 2023 |
| 80 | Prescribed Dose for Target Site 8 | PrescrDose8 |  |
| 81 | Delivered Dose for Target Site 8 | DelivDose8 |  |
| 82 | Total Fractions for Target Site 8 | TFractionsTarget8 |  |
| 83 | Treatment Technique for Target Site 8 (F) | TechTarget8 | Code 7= Paediatric obsolete from 1 July 2023 |
| 84 | Total Fields for Target Site 8 | TFieldsTarget8 |  |
| 85 | Target Site of Radiotherapy 9 | TargetSite9 | New Target Sites added 18c,19c,20c,21cEffective from 1 July 2023 |
| 86 | Prescribed Dose for Target Site 9 | PrescrDose9 |  |
| 87 | Delivered Dose for Target Site 9 | DelivDose9 |  |
| 88 | Total Fractions for Target Site 9 | TFractionsTarget9 |  |
| 89 | Treatment Technique for Target Site 9 (F) | TechTarget9 | Code 7= Paediatric obsolete from 1 July 2023 |
| 90 | Total Fields for Target Site 9 | TFieldsTarget9 |  |
| 91 | Target Site of Radiotherapy 10 | TargetSite10 | New Target Sites added 18c,19c,20c,21cEffective from 1 July 2023 |
| 92 | Prescribed Dose for Target Site 10 | PrescrDose10 |  |
| 93 | Delivered Dose for Target Site 10 | DelivDose10 |  |
| 94 | Total Fractions for Target Site 10 | TFractionsTarget10 |  |
| 95 | Treatment Technique for Target Site 10 (F) | TechTarget10 | Code 7= Paediatric obsolete from 1 July 2023 |
| 96 | Total Fields for Target Site 10 | TFieldsTarget10 |  |
| 97 | Number of Treatment Reviews | TreatReview |  |
| 98 | IGRT 2D | IGRT2D |  |
| 99 | IGRT 3D | IGRT3D |  |

## Group A patient demographic data items

### 1 Patient First Name

| Group A | Patient’s first name |
| --- | --- |
| Abbreviated name | PFirstName |
| Definition | The full first name of the patient |
| Purpose | To facilitate data linkage |
| Data type | Alpha  |
| Format | AAAAA |
| Maximum field size | Not applicable |
| Code set | n/a |
| Additional information | Enter name as appears on the Medicare cardLower case acceptable  |
| Missing data | Not acceptable |

### 2 Patient Surname (Family Name)

| Group A | Patient Surname  |
| --- | --- |
| Abbreviated name | PSurname |
| Definition | The full surname of the patient |
| Purpose | To facilitate data linkage |
| Data type | Alpha  |
| Format | AAAAA |
| Maximum field size | Not applicable |
| Code set | n/a |
| Additional information | Enter name as it appears on the Medicare cardLower case is acceptable  |
| Missing data | Not acceptable |

### 3 Patient Street Address

| Group A | Street address |
| --- | --- |
| Abbreviated name | PStreetAddr |
| Definition | Street number and name |
| Purpose | Analysis around access to services |
| Data type | Alphanumeric |
| Format | A(22) |
| Maximum field size | 22 |
| Code set | Free text |
| Missing data | Not acceptable |

### 4 Patient Locality

| Group A | Patient  |
| --- | --- |
| Abbreviated name | PLocality |
| Definition | Geographic location (suburb/town/locality for Australian residents; country for overseas residents) of usual residence of the person (not postal address) |
| Purpose | To enable calculation (with Postcode field) of the patient’s appropriate Statistical Local Area (SLA) and local government area (LGA), which enables analysis of service use and need for services, identification of patients living outside of Victoria for purposes of cross-border funding, identification of patients living outside Australia for the Reciprocal Health Care Agreement |
| Data type | Alphanumeric |
| Format | A(22) |
| Maximum field size | 22 |
| Code set | Postcode locality reference <www2.health.vic.gov.au/hospitals-and-health-services/data-reporting/health-data-standards-systems/reference-files> |
| Additional information | Only name of locality is permissible (not the code)For overseas patients, services may enter country name or ‘overseas’ where the country name is not known |
| Missing data | Not acceptable |

### 5 Patient Postcode of Residence

| Group A | Patient postcode of residence |
| --- | --- |
| Abbreviated name | PostcodeRes |
| Definition | Postcode of patient’s usual place of residence  |
| Purpose | Administrative – to inform analysis around access |
| Data type | Numeric |
| Format | NNNN |
| Maximum field size | 4 |
| Code set | [Postcode locality reference](https://www2.health.vic.gov.au/about/publications/researchandreports/postcode-locality-reference) <https://www2.health.vic.gov.au/about/publications/researchandreports/postcode-locality-reference> |
| Additional information | For overseas patients, services may enter country name or ‘overseas’ where the country name is not known |

### 6 Date of Birth

| Group A | Date of birth |
| --- | --- |
| Abbreviated name  | DoB |
| Definition | The date of birth of the patient |
| Purpose | DoB is required for a range of clinical and administrative purposes; it enables derivation of age for use in demographic analyses, and assists in the unique identification of clients if other identifying information is missing or in question |
| Data type | Date |
| Format | DD/MM/YYYY |
| Maximum field size | 10 |
| Code set | Not applicable |
| Additional information | Not applicable |
| Missing data | Not acceptable |

### 7 Sex

| Group A | Sex |
| --- | --- |
| Abbreviated name | Sex |
| Definition | The biological distinction between male and femaleWhere there is an inconsistency between anatomical and chromosomal characteristics, gender is based on anatomical characteristics |
| Purpose | This is a core data element in a wide range of social, labour and demographic statistics |
| Data type | Alpha |
| Format | M = Male, F = Female, I = Indeterminate, N = Not stated or inadequately described |
| Maximum field size | 1 |
| Code set | M or F or I or N |
| Additional information | Enter gender at birth  |
| Missing data | Not acceptable |

### 8 Medicare Number

| Group A | Medicare number |
| --- | --- |
| Abbreviated name | MedicareNo |
| Definition | Person identifier allocated by the HIC to eligible patients under the Medicare scheme that appears on a Medicare card |
| Purpose | To be used to link patients across different service providers and combine with other data items to identify duplicate course entries |
| Data type | Numeric |
| Format | N(11) |
| Required field size | 11 (inclusive of number against patient name) |
| Code set | Medicare numberNME: ‘Not Medicare Eligible’ where patients do not have a Medicare number e.g. overseas visitorsDVA numbers must be entered if the patient does not have a Medicare card |
| Additional information | Do not include hyphens, spaces, underscores, blank cells, etc. |
| Missing data | Not acceptable |

### 9 Indigenous Status

| Group A | Indigenous status |
| --- | --- |
| Abbreviated name | IndigStatus |
| Definition | Whether a person identifies as being of Aboriginal or Torres Strait Islander origin |
| Purpose | Demographic information to facilitate analysis around access to services and service planning |
| Data type | Numeric |
| Format | N |
| Maximum field size | 1 |
| Code set | 1 = Aboriginal but not Torres Strait Islander origin2 = Torres Strait Islander but not Aboriginal origin3 = Both Aboriginal and Torres Strait Islander origin4 = Neither Aboriginal nor Torres Strait Islander origin9 = Not stated or inadequately described |
| Additional information | Nil |
| Missing data | Not acceptable |

## Group B Service data items

### 10 Hospital Name

| Group B | Hospital name (or Provider name) |
| --- | --- |
| Abbreviated name | HosName |
| Definition | The name of the hub hospital or provider of the service |
| Purpose | Administrative and to inform analysis on access to services |
| Data type | Text |
| Format | Alpha |
| Maximum field size | Open |
| Code set | Refer to Appendix 2 for hospital name list |
| Additional information | Nil |
| Missing data | Not acceptable |

### 11 Hospital Code

| Group B | Hospital code (or Provider Code) |
| --- | --- |
| Abbreviated name | HosCode |
| Definition | The code of the hub hospital or provider of the service |
| Purpose | Administrative and to inform analysis on access to services |
| Data type | Numeric |
| Format | NNNN |
| Maximum field size | 4 |
| Code set | Refer to Appendix 2 for hospital/provider code list |
| Additional information | Provider name may be used in place of code where this is agreed |
| Missing data | Not acceptable |

### 12 Campus Name

| Group B | Campus name |
| --- | --- |
| Abbreviated name | CampName |
| Definition | Identifies the hospital campus where the course of radiotherapy was provided |
| Purpose | Administrative and to inform analysis on access to services |
| Data type | Alpha |
| Format | AAAA |
| Maximum field size | Open |
| Code set | Refer to Appendix 2 for campus code list |
| Additional information | Nil |
| Missing data | Not acceptable |

### 13 Campus Code

| Group B | Campus code |
| --- | --- |
| Abbreviated name | CampCode |
| Definition | Identifies the code of the hospital campus where the course of radiotherapy was provided |
| Purpose | Administrative and to inform analysis on access to services |
| Data type | Numeric |
| Format | NNNN |
| Maximum field size | 4 |
| Code set | Refer to Appendix 2 for campus code list |
| Additional information | Nil |
| Missing data | Not acceptable |

### 14 Unit Record Number

| Group B | Unit record number |
| --- | --- |
| Abbreviated name | URN |
| Definition | Hospital-specific patient identifier that is unique within an establishment or agency for that patient |
| Purpose | This item could be used for editing at the agency or collection authority level and potentially for record linkage |
| Data type | Alphanumeric |
| Format | Individual agencies or collection authorities may use their own alphabetic, numeric or alphanumeric coding systems |
| Maximum field size | 20 |
| Code set | Hospital determined |
| Additional information  | The URN may not be unique across facilities but must be unique within a facilityIt should not include apostrophes, hyphens, inflections, dashes or spacesThe name of the person should not be used as the URN |
| Missing data | Not acceptable |

### 15 Account Class

| Group B | Account class |
| --- | --- |
| Abbreviated name | AccClass |
| Definition | **Public:** The patient is referred to the radiation therapy centre for treatment and is not MBS billed**Private:** Privately insured admitted patients only**MBS:** The patient is referred to a named doctor or radiation oncologist and is Medicare billed**DVA:** The patient holds a Department of Veteran Affairs card**Shared care:** The patient is a public patient who meets the eligibility criteria for referral to a participating private radiotherapy provider**Other:** Self-funded and overseas patients |
| Purpose | Administrative and funding analysis |
| Data type | Alphanumeric |
| Format | Aa, AAA, AA, Aaaaa |
| Maximum field size | 5 |
| Code set | Pu, Pr, MBS, DVA, SC, Other |
| Additional information | Where treatment is delivered in both admitted and non-admitted settings, the account class reported should be that in which most fractions are delivered |
| Missing data | Not acceptable |

### 16 Course Id

| Group B | Course Id |
| --- | --- |
| Abbreviated name | CourseId |
| Definition | A course of radiotherapy involves:* a prescription by a radiation oncologist outlining the anatomical region/site(s) to be treated, fractionation and total dose to be delivered
* all phases of radiotherapy delivered for managing a single disease entity relating to a decision to treat
 |
| Purpose | This is required to link treatment components relating to a particular course of treatment |
| Data type | Alphanumeric |
| Format | N(20) |
| Maximum field size | 20 |
| Code set | Free |
| Additional information | All courses planned must be allocated a course number, even if they did not startEach course Id should be a unique numberSpaces. Decimals and punctation are not accepted as part of the CourseIdEach course Id can have only one modalitySee Appendix 2 for conditions determining course status See Appendix 2a for description of a KVT course |
| Missing data | Not acceptable |

### 17 Primary Site of Cancer

| Group B | Primary site of disease |
| --- | --- |
| Abbreviated name | PrimarySite |
| Definition | The primary site is the site of origin of the tumour, as opposed to the secondary or metastatic sites. It is described by reporting the anatomical origin and position of the tumour. ICD-10-AM: ICD Code (Australian modification, version 9 or later) is used to indicate the primary site of cancer for which the radiotherapy treatment is being given. The primary cancer is coded whether the treatment is being given for the primary cancer or a secondary cancer resulting from the primary cancer |
| Purpose | Monitoring the number of new cases of treatment for calculating utilisation rates and inform service planning |
| Data type | Alphanumeric |
| Format | ANN.N |
| Maximum field size | 6 |
| Code set | ICD-10-AM |
| Additional information | Do not use ICD-10 codes that describe secondary causes e.g. C77–C79.9 |
| Missing data | Not acceptable |

### 17a Primary Site of Cancer 2

| Group B | Primary site of disease 2 |
| --- | --- |
| Abbreviated name | PrimarySite 2 |
| Definition | The primary site is the site of origin of the tumour, as opposed to the secondary or metastatic sites. It is described by reporting the anatomical origin and position of the tumour. ICD-10-AM: ICD Code (Australian modification, version 9 or later) is used to indicate the primary site of cancer for which the radiotherapy treatment is being given. The primary cancer is coded whether the treatment is being given for the primary cancer or a secondary cancer resulting from the primary cancer |
| Purpose | Monitoring the number of new cases of treatment for calculating utilisation rates and inform service planning |
| Data type | Alphanumeric |
| Format | ANN.N |
| Maximum field size | 6 |
| Code set | ICD-10-AM |
| Additional information | Do not use ICD-10 codes that describe secondary causes e.g.C77–C79.9This field is to be populated only where a second primary site is diagnosed and receives bilateral treatment with VMAT or IMRT, and where TargetSite=18c,19c,20c or 21c |
| Missing data | Not acceptable |

### 18 Treating Doctor First Name

| Group B | Treating doctor’s first name |
| --- | --- |
| Abbreviated name | ROFirstName |
| Definition | The full first name of the prescribing doctor |
| Purpose | In particular, to identify the relevant doctor to approach to either: * resolve queries that may arise from the Victorian Cancer Registry quality control program; or
* to conduct Human Research Ethics Committee–approved recruitment studies.
 |
| Data type | Alpha |
| Format | AAAA |
| Maximum field size | Not applicable |
| Code set | Not applicable |
| Additional information | Nil |
| Missing data | Not acceptable |

### 19 Treating Doctor Surname (Family Name)

| Group B | Treating doctor’s surname |
| --- | --- |
| Abbreviated name | ROSurname |
| Definition | The full surname of the prescribing doctor |
| Purpose | Used to identify the relevant doctor to approach to either: * resolve queries that may arise from the Victorian Cancer Registry quality control program; or
* to conduct Human Research Ethics Committee–approved recruitment studies
 |
| Data type | Alpha |
| Format | AAAA |
| Maximum field size | Not applicable |
| Code set | Not applicable |
| Additional information | Nil |
| Missing data | Not acceptable |

### 20 Date of 1st Consultation with Radiation Oncologist

| Group B | Date of first consultation with RO |
| --- | --- |
| Abbreviated name | 1stConsultRO |
| Definition | The date when the first consultation with a radiation oncologist was attended by the patient and a prescription was produced for the reported course of treatment |
| Purpose | To generate access indicators |
| Data type | Date |
| Format | DD/MM/YYYY |
| Maximum field size | 10 |
| Code set | Not applicable |
| Additional information | Where the first consultation occurred outside the treating hospital, the service is to pursue the date as far as possible |
| Missing data | Not acceptable |

###

### 21 Radiotherapy Date Ready for Care

| Group B | Radiotherapy date ready for care |
| --- | --- |
| Abbreviated name | RFC |
| Definition | Patients are ready for care on the date on which the radiation oncologist and the patient agree to radiotherapy treatmentRefer to Appendix 3 for full definition |
| Purpose | Quality analysis: access to radiotherapy, wait times |
| Data type | Date |
| Format | DD/MM/YYYY |
| Maximum field size | 10 |
| Code set | Not applicable |
| Additional information | Refer to Appendix 3 for further information |
| Missing data | Not acceptable |

### 22 Radiotherapy Treatment Start Date

| Group B | Radiotherapy start date  |
| --- | --- |
| Abbreviated name | StartDate |
| Definition | The date on which the patient begins a course of treatment |
| Purpose | Quality analysis: access to radiotherapy, wait times |
| Data type | Date |
| Format | DD/MM/YYYY |
| Maximum field size | 10 |
| Code set | Not applicable |
| Additional information | Nil |
| Missing data | Acceptable if patient did not start |

### 23 Radiotherapy Treatment Completion Date

| Group B | Radiotherapy course completion date  |
| --- | --- |
| Abbreviated name | CompletionDate |
| Definition | Date of last fraction |
| Purpose | Quality analysis: access to radiotherapy, wait times |
| Data type | Date |
| Format | DD/MM/YYYY |
| Maximum field size | 10 |
| Code set | Not applicable |
| Additional information | Nil |
| Missing data | Acceptable if patient did not start  |

### 24 New Treatment / Retreatment

| Group B | New treatment/retreatment |
| --- | --- |
| Abbreviated name | NewTreat/Retreat |
| Definition | New treatment: patients receiving a first course of radiotherapy for a particular primary cancer diagnosisRetreatment: a subsequent course of radiotherapy after the patient has previously received a course of radiotherapy for the same primary diagnosis, regardless of the body site or Victorian facility at which other courses were provided |
| Purpose | To calculate radiotherapy utilisation rates for service planning |
| Data type | Text |
| Format | Alpha |
| Maximum field size | 1 |
| Code set | N = New treatmentR = Retreatment |
| Additional information | Nil |
| Missing data | Not acceptable |

### 25 Intention of Radiotherapy Treatment

| Group B | Intention of radiotherapy treatment  |
| --- | --- |
| Abbreviated name | Intent |
| Definition | The reason treatment is provided to a patient as represented by a code |
| Purpose | Quality analysis: access to radiotherapy, wait times |
| Data type | Number |
| Format | N |
| Maximum field size | 1 |
| Code set | 1 = Prophylactic2 = Radical3 = Palliative4 = Other5 = Emergency |
| Additional information | Refer to Appendix 4 for a description of codes |
| Missing data | Not acceptable |

### 26 Simulation 1

| Group B | Simulation 1 |
| --- | --- |
| Abbreviated name | Sim1 |
| Definition | First simulation |
| Purpose | To count the number of simulations for funding purposes |
| Data type | Alphanumeric |
| Format | AAAAAAN or AAAAAAN.N |
| Maximum field size | < 9 |
| Code set | OPSimL1OPSimL2OPSimL3OPSimL3.1OPSimL4IPSimL1IPSimL2IPSimL3IPSim3.1IPSimL4MROPSimL3MROPSimL3.1MROPSimL4MRIPSimL3MRIPSimL3.1MRIPSimL4 |
| Additional information | SXRT courses should not have a Sim entryMR refers to simulation done on a magnetic resonance simulator |
| Missing data | Acceptable only where no Sim is provided |

### 27 Simulation 2

| Group B | Simulation 2 |
| --- | --- |
| Abbreviated name | Sim2 |
| Definition | Second simulation for the course |
| Purpose | To count the number of simulations for funding purposes |
| Data type | Alphanumeric |
| Format | AAAAAAN or AAAAAAN.N |
| Maximum field size | < 9 |
| Code set | OPSimL1OPSimL2OPSimL3OPSimL3.1OPSimL4IPSimL1IPSimL2IPSimL3IPSim3.1IPSimL4MROPSimL3MROPSimL3.1MROPSimL4MRIPSimL3MRIPSimL3.1MRIPSimL4~~None~~ |
| Additional information | This may be a re-simulation of the same site or a new site to be treated during the same courseSXRT courses should not have a Sim entryMR refers to simulation done on a magnetic resonance simulator |
| Missing data | Acceptable only where no Sim is provided |

### 28 Simulation 3

| Group B | Simulation 3 |
| --- | --- |
| Abbreviated name | Sim3 |
| Definition | Third simulation for the course |
| Purpose | To count the number of simulations for funding purposes |
| Data type | Numeric |
| Format | AAAAAAN or AAAAAAN.N |
| Maximum field size | < 9 |
| Code set | OPSimL1OPSimL2OPSimL3OPSimL3.1OPSimL4IPSimL1IPSimL2IPSimL3IPSim3.1IPSimL4MROPSimL3MROPSimL3.1MROPSimL4MRIPSimL3MRIPSimL3.1MRIPSimL4 |
| Additional information | This may be a re-simulation of the same site or a new site to be treated during the same courseSXRT courses should not have a Sim entryMR refers to simulation done on a magnetic resonance simulator |
| Missing data | Acceptable only where no Sim is provided |

### 29 Dosimetry 1

| Group B | Dosimetry 1 |
| --- | --- |
| Abbreviated name | Dos1 |
| Definition | First dosimetry |
| Purpose | To count the number of dosimetric plans for funding purposes |
| Data type | Alphanumeric |
| Format | AAAAAAN *or* AAAAAAN.N *or* AAA-AAAAAAN |
| Maximum field size | < 11 |
| Code set | CTDosL1CTDosL2CTDosL3CTDosL3.1CTDosL4CTDosL4.1CTDosL5Non-CTDosL1Non-CTDosL2Non-CTDosL3~~None~~ |
| Additional information | Dosimetry done on an MR scan should use the equivalent CT Dos CodesSXRT courses should not have a Dos entry |
| Missing data | Acceptable only where no Dos is provided |

### 30 Dosimetry 2

| Group B | Dosimetry 2 |
| --- | --- |
| Abbreviated name | Dos2 |
| Definition | Second dosimetry |
| Purpose | To count the number of dosimetric plans for funding purposes |
| Data type | Alphanumeric |
| Format | AAAAAAN *or* AAAAAAN.N *or* AAA-AAAAAAN  |
| Maximum field size | < 11 |
| Code set | CTDosL1CTDosL2CTDosL3CTDosL3.1CTDosL4CTDosL4.1CTDosL5Non-CTDosL1Non-CTDosL2Non-CTDosL3~~None~~ |
| Additional information | Use for re-plan, for subsequent phase of dosimetry or dosimetry to a new site being treated during the courseSXRT courses should not have a Dos entryDosimetry done on an MR scan should use the equivalent CT Dos Codes |
| Missing data | Acceptable only where no Dos is provided |

### 31 Dosimetry 3

| Group B | Dosimetry 3 |
| --- | --- |
| Abbreviated name | Dos3 |
| Definition | Third dosimetry |
| Purpose | To count the number of dosimetric plans for funding purposes |
| Data type | Alphanumeric |
| Format | AAAAAAN *or* AAAAAAN.N *or* AAA-AAAAAAN |
| Maximum field size | < 11 |
| Code set | CTDosL1CTDosL2CTDosL3CTDosL3.1CTDosL4CTDosL4.1CTDosL5Non-CTDosL1Non-CTDosL2Non-CTDosL3 |
| Additional information | Use for re-plan, for subsequent phase of dosimetry or dosimetry to a new site being treated during the courseSXRT courses should not have a Dos entryDosimetry done on an MR scan should use the equivalent CT Dos Codes |
| Missing data | Acceptable only where no Dos is provided |

### 32 Treatment Modality

| Group B | Treatment modality |
| --- | --- |
| Abbreviated name | Modality |
| Definition | Identifies the type of radiation equipment used |
| Purpose | To inform analysis on access to treatment mode, funding and service planning |
| Data type | Numeric |
| Format | N |
| Maximum field size | 1 |
| Code set | 1 = MVT (megavoltage therapy)2 = BRY (brachytherapy)3 = KVT (kilovoltage therapy)4 = Co60 (Cobalt60)5 = MRMV (magnetic resonance megavoltage linac) |
| Additional information | Nil |
| Missing data | Not acceptable |

### 33 Total Radiation Fractions

| Group B | Radiation fractions |
| --- | --- |
| Abbreviated name | TotalFractions |
| Definition | The number of radiotherapy fractions delivered during the course of radiationThis reflects the number of patient attendances for treatment (excluding planning and consultations) |
| Purpose | Provides the total number of attendances for a course of treatment |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Includes inpatient and outpatient fractions (for the same course)Where only one target site is treated, TotalFractions equals the number under TFractionsTarget1Where multiple target sites are treated, TotalFractions should equal up to sum of fractions of all TargetSites provided in the course. Cancelled courses must be included (include fractions for courses partly finished)Enter ‘0’ fractions for courses planned but not treatedWhere a patient receives two fractions per day (a second attendance on the same day), this is reported as two fractionsWhere a patient receives a sequential electron-boost following breast MV treatment, total fractions should be the sum of the fractions including the boost |
| Missing data | Not acceptable |

### 34 Total Number of Fields

| Group B | Total number of fields |
| --- | --- |
| Abbreviated name | TotalFields |
| Definition | The number of fields delivered during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | TotalFields is the sum of the fields delivered to each of the target sitesA field count entry for courses that were not completed must be included Enter ‘0’ field count for courses that were planned but not treatedFor data items 41, 47, 53, 59 where TreatTechnique is 17 = VMAT or 18 = SRT/SBRT enter number arcs: where 1 arc = 1 field, 2 arcs = 2 fields, etc.Where modality = BRY, TotalFields should equal 0 |
| Missing data | Not acceptable |

### 35 Inpatient Fractions

| Group B | Inpatient fractions |
| --- | --- |
| Abbreviated name | InpFractions |
| Definition | The total number of fractions delivered during an inpatient admission |
| Purpose | To distinguish non-admitted radiotherapy activity from admitted activity |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Nil |
| Missing data | Not acceptable |

### 36 Inpatient Fields

| Group B | Inpatient fields |
| --- | --- |
| Abbreviated name | InpFields |
| Definition | The total number of fields/arcs delivered as part of an inpatient admission |
| Purpose | To distinguish non-admitted activity from admitted activity and calculate weighted activity units for treatments eligible for funding |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Nil |
| Missing data | Not acceptable |

### 37 Target Site of Radiotherapy 1

| Group B  | Target site of radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite1 |
| Definition | The anatomical site or region of the body that is the target of a particular radiotherapy treatmentIdentifies the anatomic target of the most clinically significant region of radiation therapy delivered to the patient during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric ± alpha |
| Format | NN, NNA |
| Maximum field size (per site) | 3 |
| Code set | VRMDS target site list (refer to Appendix 6) |
| Additional information | Multiple target sites to be entered into individual columns and matched to corresponding prescribed dose, delivered dose, fractions, technique and field columnsIt is preferred that the target site with the most fractions is placed first |
| Missing data | Not acceptable |

### 38 Prescribed Dose for Target Site 1

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose1 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for by the radiation oncologist |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Not acceptable |

### 39 Delivered Dose for Target Site 1

| Group B | Delivered dose |
| --- | --- |
| Abbreviated name | DelivDose1 |
| Definition | The dose that is a sum of the fractional doses delivered to the target site for the course of radiotherapy, as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number If treatment did not begin, enter ‘0’ |
| Missing data | Not acceptable |

### 40 Total Fractions for Target Site 1

| Group B | Total number of fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget1 |
| Definition | The number of fractions delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | The total number of fractions must be reported for the corresponding target site number A fraction entry for courses that were not completed must be includedEnter a ‘0’ fraction count for courses that were planned but not treated |
| Missing data | Not acceptable |

### 41 Treatment Technique for Target Site 1

| Group B | Treatment technique  |
| --- | --- |
| Abbreviated name | TechTarget1 |
| Definition | Identifies the treatment/technique type |
| Purpose | To identify trends in treatment techniques for service and budget planning |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS (using frame, also includes SABR)5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definitions of the codesThe reported technique is the technique used for Target Site 1 |
| Missing data | Not acceptable |

### 42 Total Fields for Target Site 1

| Group B | Total number of fields target site |
| --- | --- |
| Abbreviated name | TFieldsTarget1 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | The total number of fields must be reported for the corresponding target site numberA field entry for treatment begun but not completed must be includedEnter an ‘0’ field count for courses that were planned but not treatedWhere modality = BRY, TotalFields should equal 0Where TreatTechnique is 17 = VMAT or 18 = SRT/SBRT enter number of arcs: 1 arc = 1 field, 2 arcs = 2 fields, etc. |
| Missing data | Not acceptable |

### 43 Target Site of Radiotherapy 2

| Group B  | Target site of radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite2 |
| Definition | The site or region of the body that is the target of a particular radiotherapy treatmentIdentifies the second anatomical target site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size (per site) | 3 |
| Code set | VRMDS target site list (refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a second target site is not planned |

### 44 Prescribed Dose for Target Site 2

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose2 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for by the radiation oncologist |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a second target site is not prescribed |

### 45 Delivered Dose for Target Site 2

| Group B | Delivered dose |
| --- | --- |
| Abbreviated name | DelivDose2 |
| Definition | The dose that is a sum of the fractional doses delivered to the target site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a second target site is not treated |

### 46 Total Fractions for Target Site 2

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget2 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number  |
| Missing data | Leave blank only when a secondtarget site is not treated |

### 47 Treatment Technique for Target Site 2

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget2 |
| Definition | Identifies the treatment type |
| Purpose | To identify trends in treatment techniques for service and budget planning |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definitions of the codesThe reported technique is the technique used for Target Site 2 |
| Missing data | Leave blank only when a second target site is not treated |

### 48 Total Fields for Target Site 2

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget2 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number Where modality = BRY, TotalFields should equal 0Where TreatTechnique is 17 = VMAT or 18 = SRT/SBRT enter number of arcs: 1 arc = 1 field, 2 arcs = 2 fields, etc. |
| Missing data | Leave blank only when a second target site is not treated |

### 49 Target Site of Radiotherapy 3

|  |  |
| --- | --- |
| Group B  | Target site of radiotherapy |
| Abbreviated name | TargetSite3 |
| Definition | The site or region of the body that is the target of a particular radiotherapy treatmentIdentifies the third anatomical target site to which radiation therapy delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 2 |
| Code set | VRMDS target site list (Refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a third target site is not planned |

### 50 Prescribed Dose for Target Site 3

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose3 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist  |
| Purpose | To meet reporting requirements under Schedule 1 Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number  |
| Missing data | Leave blank only when a third target site is not prescribed |

### 51 Delivered Dose for Target Site 3

| Group B | Delivered dose |
| --- | --- |
| Abbreviated name | DelivDose3 |
| Definition | The dose that is a sum of the fractional doses delivered to the primary site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank when a third Target Site is not treated |

### 52 Total Fractions for Target Site 3

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget3 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank when a third Target Site is not treated |

### 53 Treatment Technique for Target Site 3

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget3 |
| Definition | Identifies the treatment type |
| Purpose | To identify trends in treatment techniques for service and budget planning |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT)  |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for Target Site 3 |
| Missing data | Leave blank only when a third target site is not treated |

### 54 Total Fields for Target Site 3

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget3 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number Where Modality =BRY, Total Fields should equal 0Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a third Target Site is not treated |

### 55 Target Site of Radiotherapy 4

| Group B  | Target Site of Radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite4 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the fourth anatomical site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 2 |
| Code set | VRMDS Target Site list (refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a fourth Target Site is not planned |

###

### 56 Prescribed Dose for Target Site 4

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose4 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a fourth target site is not prescribed |

### 57 Delivered Dose for Target Site 4

|  |  |
| --- | --- |
| Group B | Delivered Dose |
| Abbreviated name | DelivDose4 |
| Definition | The dose that is a sum of the fractional doses delivered to the target site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank when a fourth target site is not treated |

###

### 58 Total Fractions for Target Site 4

| Group B | Radiation Fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget4 |
| Definition | The number of radiotherapy fractions delivered to the Target Site during the course of radiation per Target Site |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a fourth target site is not treated |

### 59 Treatment Technique for Target Site 4

| Group B | Treatment Technique |
| --- | --- |
| Abbreviated name | TechTarget4 |
| Definition | Identifies the treatment type |
| Purpose | To identify trends in treatment techniques for service and budget planning  |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for Target Site 4 |
| Missing data | Leave blank only when a fourth target site is not treated |

### 60 Total Fields for Target Site 4

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget4 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site numberWhere Modality =BRY, Total Fields should equal 0.Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a fourth target site is not treated |

### 61 Target Site of Radiotherapy 5

| Group B  | Target site of radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite5 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the fourth anatomical site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 2 |
| Code set | VRMDS Target Site list (Refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a fifth target site is not planned |

### 62 Prescribed Dose for Target Site 5

|  |  |
| --- | --- |
| Group B | Prescribed dose |
| Abbreviated name | PrescrDose5 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a fifth target site is not prescribed |

### 63 Delivered Dose for Target Site 5

| Group B | Delivered dose |
| --- | --- |
| Abbreviated name | DelivDose5 |
| Definition | The dose that is a sum of the fractional doses delivered to the Target Site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank when a fifth target site is not treated |

### 64 Total Fractions for Target Site 5

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget4 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation per target site |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a 5th target site is not treated |

### 65 Treatment Technique for Target Site 5

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget5 |
| Definition | Identifies the treatment type |
| Purpose | To identify trends in treatment techniques for service and budget planning |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for Target Site 4 |
| Missing data | Leave blank only when a 5th target site is not treated |

### 66 Total Fields for Target Site 5

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget5 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site numberWhere Modality=BRY, Total Fields should equal 0Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a fifth target site is not treated |

### 67 Target Site of Radiotherapy 6

|  |  |
| --- | --- |
| Group B  | Target site of radiotherapy |
| Abbreviated name | TargetSite6 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the second anatomical target site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 3 |
| Code set | VRMDS Target Site list (Refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a sixth target site is not planned |

### 68 Prescribed Dose for Target Site 6

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose6 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist  |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number |
| Missing data | Leave blank only when a sixth target site is not prescribed |

### 69 Delivered Dose for Target Site 6

|  |  |
| --- | --- |
| Group B | Delivered dose |
| Abbreviated name | DelivDose6 |
| Definition | The dose that is a sum of the fractional doses delivered to the Target Site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS)  |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data must correspond to the treated target site number |
| Missing data | Leave blank only when a sixth target site is not treated |

### 70 Total Fractions for Target Site 6

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget6 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation.  |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Fraction data must correspond to the treated target site number |
| Missing data | Leave blank only when a sixthtarget site is not treated  |

### 71 Treatment Technique for Target Site 6

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget6 |
| Definition | Identifies the treatment type.  |
| Purpose | To identify trends in treatment techniques for service and budget planning.  |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for Target Site 2 |
| Missing data | Leave blank only when a sixth target site is not treated |

### 72 Total Fields for Target Site 6

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget6 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data must correspond to the treated target site numberWhere Modality =BRY, Total Fields should equal 0Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a sixth target site is not treated |

### 73 Target Site of Radiotherapy 7

| Group B  | Target site of radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite7 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the fourth anatomical site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 2 |
| Code set | VRMDS Target Site list (Refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a seventh target site is not planned |

### 74 Prescribed Dose for Target Site 7

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose7 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data must correspond to the treated target site number |
| Missing data | Leave blank only when a seventh target site is not prescribed |

### 75 Delivered Dose for Target Site 7

| Group B | Delivered Dose |
| --- | --- |
| Abbreviated name | DelivDose7 |
| Definition | The dose that is a sum of the fractional doses delivered to the Target Site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Dose data must correspond to the treated target site number |
| Missing data | Leave blank when a seventh target site is not treated |

### 76 Total Fractions for Target Site 7

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget7 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation per target site |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data must correspond to the treated target site number |
| Missing data | Leave blank only when a seventh target site is not treated |

### 77 Treatment Technique for Target Site 7

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget7 |
| Definition | Identifies the treatment type  |
| Purpose | To identify trends in treatment techniques for service and budget planning.  |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for target site 7 |
| Missing data | Leave blank only when a seventh target site is not treated |

### 78 Total Fields for Target Site 7

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget7 |
| Definition | The number of fields delivered to the Target Site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis. |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data must correspond to the treated target site number. Where Modality =BRY, Total Fields should equal 0.Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a seventh target site is not treated |

### 79 Target Site of Radiotherapy 8

| Group B  | Target site of radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite8 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the fourth anatomical site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 2 |
| Code set | VRMDS Target Site list (Refer to Appendix 6) |
| Additional information |  |
| Missing data | Leave blank only when an eighth target site is not planned |

### 80 Prescribed Dose for Target Site 8

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose5 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist  |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data must correspond to the treated target site number  |
| Missing data | Leave blank only when an eighth target site is not prescribed |

### 81 Delivered Dose for Target Site 8

|  |  |
| --- | --- |
| Group B | Delivered dose |
| Abbreviated name | DelivDose8 |
| Definition | The dose that is a sum of the fractional doses delivered to the Target Site for the course of radiotherapy (as recorded in the Radiation Oncology Information System) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data must correspond to the treated target site number  |
| Missing data | Leave blank when an eighth target site is not treated |

### 82 Total Fractions for Target Site 8

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget4 |
| Definition | The number of radiotherapy fractions delivered to the Target Site during the course of radiation per target site |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data must correspond to the treated target site number |
| Missing data | Leave blank only when a eighth target site is not treated |

### 83 Treatment Technique for Target Site 8

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget8 |
| Definition | Identifies the treatment type |
| Purpose | To identify trends in treatment techniques for service and budget planning |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for Target Site 8 |
| Missing data | Leave blank only when an eighth target site is not treated |

### 84 Total Fields for Target Site 8

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget8 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data must correspond to the treated target site numberWhere Modality =BRY, Total Fields should equal 0.Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when an eighth target site is not treated. |

### 85 Target Site of Radiotherapy 9

| Group B  | Target site of radiotherapy |
| --- | --- |
| Abbreviated name | TargetSite9 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the second anatomical target site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 3 |
| Code set | VRMDS Target Site list (Refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a ninth target site is not planned |

### 86 Prescribed Dose for Target Site 9

| Group B | Prescribed dose |
| --- | --- |
| Abbreviated name | PrescrDose9 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist  |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data must correspond to the treated target site number  |
| Missing data | Leave blank only when a ninth target site is not prescribed  |

### 87 Delivered Dose for Target Site 9

| Group B | Delivered dose |
| --- | --- |
| Abbreviated name | DelivDose9 |
| Definition | The dose that is a sum of the fractional doses delivered to the Target Site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data must correspond to the treated target site number  |
| Missing data | Leave blank only when a ninth target site is not treated |

### 88 Total Fractions for Target Site 9

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget9 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data must correspond with the treated target site number  |
| Missing data | Leave blank only when a ninth target site is not treated  |

### 89 Treatment Technique for Target Site 9

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget9 |
| Definition | Identifies the treatment type  |
| Purpose | To identify trends in treatment techniques for service and budget planning  |
| Data type | Numeric or Alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT) |
| Additional information | Refer to Appendix 5 for definition of codes |
| Missing data | Leave blank only when a ninth target site is not treated |

### 90 Total Fields for Target Site 9

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget9 |
| Definition | The number of fields delivered to the target site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number Where Modality =BRY, Total Fields should equal 0.Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a ninth target site is not treated |

### 91 Target Site of Radiotherapy 10

|  |  |
| --- | --- |
| Group B  | Target site of radiotherapy |
| Abbreviated name | TargetSite10 |
| Definition | The site or region of the body which is the target of a particular radiotherapy treatment. Identifies the fourth anatomical site to which radiation therapy is delivered during the course of treatment |
| Purpose | To identify the anatomical structures targeted by the radiotherapy and to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted |
| Data type | Numeric or alphanumeric |
| Format | NN or NNA |
| Maximum field size | 2 |
| Code set | VRMDS Target Site list (Refer to Appendix 6) |
| Additional information | Nil |
| Missing data | Leave blank only when a tenth target site is not planned |

### 92 Prescribed Dose for Target Site 10

|  |  |
| --- | --- |
| Group B | Prescribed dose |
| Abbreviated name | PrescrDose10 |
| Definition | The maximum dose level to the target site as ordered/prescribed and signed for, by the radiation oncologist  |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number  |
| Missing data | Leave blank only when a tenth target site is not prescribed |

### 93 Delivered Dose for Target Site 10

|  |  |
| --- | --- |
| Group B | Delivered dose |
| Abbreviated name | DelivDose10 |
| Definition | The dose that is a sum of the fractional doses delivered to the Target Site for the course of radiotherapy as recorded in the Radiation Oncology Information System (ROIS) |
| Purpose | To meet reporting requirements under Schedule 1 of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2015 |
| Data type | Numeric |
| Format | NN.NN |
| Maximum field size | 5 |
| Code set | Measurement Unit: Gray (Gy) |
| Additional information | Data entered must correspond to the treated target site number  |
| Missing data | Leave blank when a tenth target site is not treated |

### 94 Total Fractions for Target Site 10

| Group B | Radiation fractions  |
| --- | --- |
| Abbreviated name | TFractionsTarget10 |
| Definition | The number of radiotherapy fractions delivered to the target site during the course of radiation per target site |
| Purpose | Describes the course of radiotherapy |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number  |
| Missing data | Leave blank only when a tenth target site is not treated |

### 95 Treatment Technique for Target Site 10

| Group B | Treatment technique |
| --- | --- |
| Abbreviated name | TechTarget10 |
| Definition | Identifies the treatment type  |
| Purpose | To identify trends in treatment techniques for service and budget planning  |
| Data type | Numeric or alphanumeric |
| Format | N or NN or Na |
| Maximum field size | 2 |
| Code set | 1 = RT 3 = IMRT 5 = SRS includes SABR5a = SRF (stereotactic radiosurgery frameless) 9 = TBE 9a = TBI 10 = Intracavitary (BRY) 11 = Intraluminal (BRY) 12 = Interstitial (BRY) 13 = Surface applications (BRY) 14 = Low-dose rate seeds 15 = SXRT 16 = DXRT 17 = VMAT (volumetric modulated arc therapy)18 = SRT includes SBRT19 = Gated RT20 = Adaptive RT 21 = Intraoperative radiotherapy (IORT)  |
| Additional information | Refer to Appendix 5 for definition of codesThe reported technique is the technique used for Target Site 10 |
| Missing data | Leave blank only when a tenth target site is not treated |

### 96 Total Fields for Target Site 10

| Group B | Total number of fields by target site |
| --- | --- |
| Abbreviated name | TFieldsTarget10 |
| Definition | The number of fields delivered to the Target Site during the course of radiotherapy |
| Purpose | To measure complexity for funding purposes and contribute to dose analysis |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Not applicable |
| Additional information | Data entered must correspond to the treated target site number Where Modality =BRY, Total Fields should equal 0Where TreatTechnique is 17=VMAT or 18=SRT/SBRT enter number of arcs: 1 arc=1 field, 2 arcs =2 fields etc. |
| Missing data | Leave blank only when a tenth Target site is not treated |

### 97 Number of Treatment Reviews

| Group B | Treatment review |
| --- | --- |
| Abbreviated name | TreatReview |
| Definition | A consultation with the radiation oncologist during the course of treatment |
| Purpose | To count the number of treatment reviews provided during the course of treatment for funding and costing purposes |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Not applicable |
| Additional information | Include booked appointments with radiation therapists |
| Missing data | Not acceptable |

### 98 IGRT 2D

| Group B | IGRT 2D |
| --- | --- |
| Abbreviated name | IGRT2D |
| Definition | Image-guided radiation therapy using 2D kV or mV planar images |
| Purpose | To identify use of lower cost 2D imaging used in conjunction with specific treatment techniquesThis will inform cost and funding analyses |
| Data type | Numeric |
| Format | NNN |
| Maximum field size | 3 |
| Code set | Volume  |
| Additional information | Applies to imaging undertaken for position verificationMay be used in conjunction with 3D IGRT |
| Missing data | Not acceptable (enter ‘0’ where not used) |

### 99 IGRT 3D

| Group B | IGRT 3D |
| --- | --- |
| Abbreviated name | IGRT3D |
| Definition | Image-guided radiation therapy using 3D volumetric images |
| Purpose | To identify use of high-cost 3D imaging used in conjunction with specific treatment techniquesThis will inform cost and funding analyses |
| Data type | Numeric |
| Format | NN |
| Maximum field size | 2 |
| Code set | Volume (range: 1–50) |
| Additional information | May be used in conjunction with 2D IGRT |
| Missing data | Not acceptable (enter ‘0’ where not used) |

# Section 3: File format, data transfer procedures, privacy and confidentiality

* Use the Microsoft Excel file format.
* File naming convention: VRMDS\_ProviderName\_MonthYYYY\_Version#

Example:

* First submission: VRMDS\_Alfred\_July2022\_V1
* Any re-submission: VRMDS\_Alfred\_July2022\_V2 (…..V3….etc)
* Every file must submit data items in the order they are listed in Section 2: Data items (list).
* Column headers must follow the ‘Abbreviated name’ provided against each data item in the specifications.
* Codes must comply with the code set and format specified for each data item.
* Only ICD-10-AM diagnosis codes can be used.
* There must be no hidden rows, columns or data tabs.
* Data files are to be lodged in the department’s Secure Data Exchange.
* The password must also be provided in a separate email or by telephone.

Data must be submitted to the Department of Health by emailing the Cancer Services & Information Unit <Radiotherapy.VRMDS@health.vic.gov.au>.

# Section 4: Access to data

Radiotherapy providers and other external organisations may request data from the department by emailing the Cancer Services & Information Unit <Radiotherapy.VRMDS@health.vic.gov.au>.

* Requests for data will be assessed on a case-by-case basis.
* The department will aim to respond to requests submitted within 10 business days of receipt.
* The requesting organisation will be required to complete a Data Request Form and sign a Department of Health *Conditions of release* document.

# Appendix 1: Hospital and campus name and code list

The following table lists the hospital/provider name and code, and the campus name and code for all Victorian providers of radiotherapy services for the purposes of data lodgements to the VRMDS.

The HosCode and CampCode are generated by the Department of Health and are made available when radiotherapy services begin at a location.

|  |  |  |  |
| --- | --- | --- | --- |
| Hospital/provider name | Hospital/ provider code | Campus name | Campus/clinical site code |
| Alfred Health  | 1010 | Latrobe Regional Hospital (Traralgon) | 2440 |
| Alfred Health  | 1010 | The Alfred (Prahran) | 1010 |
| Austin Hospital | 1031 | Austin Hospital | 1031 |
| Austin Hospital | 1031 | Ballarat Regional Integrated Cancer Centre (located at Ballarat Health Services) | 2010 |
| Austin Hospital | 1031 | Stawell Austin Radiation Oncology Service (located at Stawell Regional Health) | 2260 |
| Barwon Health | 2050 | University Hospital Geelong | 2050 |
| GenesisCare | GenesisCare | Albury Wodonga Regional Cancer Centre | 1650 |
| GenesisCare | GenesisCare | Casey Radiation Oncology Centre | 8250 |
| GenesisCare | GenesisCare | Frankston Radiation Oncology Centre | 8231 |
| GenesisCare | GenesisCare | GenesisCare Radiation Oncology Centre, St Vincent’s Hospital Melbourne | 8234 |
| GenesisCare | GenesisCare | Ringwood Radiation Oncology Centre | 8232 |
| GenesisCare | GenesisCare | Western Radiation Oncology Centre | 8240 |
| GenesisCare | GenesisCare | GenesisCare Radiation Oncology Centre, Cabrini (Malvern) | 8236 |
| GenesisCare | GenesisCare | Epping Radiation Oncology Centre | 8230 |
| GenesisCare | GenesisCare | GenesisCare (Shepparton) | 8252 |

|  |  |  |  |
| --- | --- | --- | --- |
| Hospital/provider name | Hospital/provider code | Campus name | Campus/clinical site code |
| ICON Cancer Care | ICON | ICON (Mulgrave) (located at Mulgrave Private Hospital)  | 8235 |
| ICON Cancer Care | ICON | Epworth Freemasons | 6470 |
| ICON Cancer Care | ICON | Epworth Hospital [Richmond] | 6490 |
| ICON Cancer Care | ICON | South West Regional Cancer Centre | 6340 |
| ICON Cancer Care | ICON | ICON Moreland (located at John Fawkner Private Hospital, Coburg) | 8253 |
| ICON Cancer Care | ICON | ICON (Waurn Ponds) (located at Epworth Geelong Hospital, Waurn Ponds) | 8239 |
| ICON Cancer Care | ICON | ICON (Holmesglen) (located at Holmesglen Private Hospital) | 8251 |
| ICON Cancer Care | ICON | ICON (Mildura)  | 8259 |
| Peter MacCallum Cancer Centre | 1550 | Bendigo Hospital | 1021 |
| Peter MacCallum Cancer Centre | 1550 | Box Hill (Epworth Eastern Hospital) | 7370 |
| Peter MacCallum Cancer Centre | 1550 | Monash Medical Centre [Moorabbin] | 1220 |
| Peter MacCallum Cancer Centre | 1550 | Peter MacCallum Cancer Institute (Parkville) | 1550 |
| Peter MacCallum Cancer Centre | 1550 | Sunshine Hospital | 1390 |

# Appendix 2: Course ID

| Condition | New or **s**ame **c**ourse |
| --- | --- |
| Presentation with two primary diagnoses  | New course for each primary Additional information:Where there is ​bilateral breast cancer diagnosis with two different primary sites (e.g. ICD-10-AM C50.2, C50.3), these should be entered as two separate courses.Where there is a diagnosis of bilateral breast cancer with the same ICD code due to the tumour location and both the left and right breasts have the same ICD code (e.g. C50.4), this must be entered as one course, with two target sites. |
| Additional primary site identified during original treatment | New course (due to new decision to treat)Treat simultaneously on 2 course IDs |
| Additional primary site(s) on same patient commenced after original treatment | New course [create new CourseID] |
| Same site with a planned breakNew planning (e.g. due to weight loss)Concurrent chemo/radio no longer suitable due to toxicity | Same course [continue with original CourseID] |
| Re-treatment (previously treated primary area) – new planning | New course [create new CourseID] |
| Secondary cancer site  | Same course if planned and treated with the same modality during treatment of primary cancer [continue with original CourseID]New course if treatment begun after completing a previous course [create new CourseID] |
| PalliativeOne prescription with 3–4 sites | Same course [treat in a single CourseID] |
| Modality change e.g. MVT followed by BRY or SXRT  | New course [create a new CourseID whenever there is a change of modality] |
| Multiple-phase treatmentsReduced field sizesElectron boosts | Same course [treat in a single CourseID](Where the modality remains the same, for VRMDS purposes, multi-phase treatments are considered part of the same course. While the form of radiation may change, the equipment used to produce the radiation remains the same, hence the modality remains the same.) |

# Appendix 2a: Kilovoltage (KVT) course description

| KVT **c**ourse | Description |
| --- | --- |
| SXRT single | 1 attendance for 1 area |
| SXRT multi | 1 attendance for 2 or more areasMulti attendance |
| DXRT single | 1 attendance and 1 area |
| DXRT multi | 1 attendance for 2 or more fields/areasMulti attendance |

# Appendix 3: Ready for care

|  |
| --- |
| The purpose of collecting the ready-for-care date is to enable the calculation of wait times for radiotherapy treatment.Illustrative guidelines and examples of how to determine a ready-for-care date are included below. **Category A: Factors that are expected to influence the ready-for-care date**Patients are ready for care on the date on which the radiation oncologist and the patient agree to radiotherapy treatment, unless any of the following apply:1. The radiation oncologist considers treatment should not begin because the patient requires other treatment prior to radiotherapy. This prior treatment may be for the same morbidity as the intended radiotherapy or a comorbidity. Examples of prior treatments include hormone therapy, chemotherapy, surgery, other types of radiotherapy (e.g. brachytherapy) or dental work. This excludes treatments that would not have been necessary if the patient could have been treated by their ready-for-care date, for example, using chemotherapy to prevent tumour progression during the waiting time (see example scenarios i and v below).
2. The radiation oncologist considers treatment should not begin because the patient is in a postoperative, post-chemotherapy or other type of healing phase.
3. The radiation oncologist must wait for the results of a test or other information required as part of the decision-making process to set a ready-for-care date. For example: a patient has had previous radiotherapy and access to detailed information on what was previously treated needs to be established before a decision can be made on how to proceed, or a patient has had insufficient clinical workup before referral.
4. A delay is requested by the patient, or the patient delays their decision to agree to treatment (see example scenario ii).
5. The patient declines radiotherapy treatment (in this case, there is no ready-for-care date).

In situations 1 to 4 above, the ready-for-care date is the first date the patient is ready for care following these delays. In situation 5, the patient is not given a ready-for-care date. **Category B: Factors that are not expected to influence the ready-for-care date**The following are delays not expected to influence the ready-for-care date. Therefore, the patient is ready for care on the date on which the radiation oncologist and the patient agree to radiotherapy treatment, or the first date following a category A delay as listed above, even though one or more of the following might apply:1. The service is not usually open on that day (e.g. weekends and public holidays) (see example scenario iii).
2. The service does not usually start courses of radiotherapy treatment on that day (e.g. Fridays) (see example scenario iii).
3. The service cannot provide treatment on that day for other reasons either within or outside the control of the service (e.g. waiting lists, staff shortages, equipment unavailability or breakdown, industrial action, etc.) (see example scenario ii).
4. The necessary preparatory activities involved in planning and simulation such as imaging and tests have not been completed by that day, assuming that these tests are not required to make a decision about the ready-for-care date (see example scenario iv).
5. The patient might become temporarily not ready for care due to a category A delay that occurred after previously being ready for care. This includes situations where the patient is referred to other treatments (e.g. chemotherapy or hormone therapy) used to fill the gap in treatment caused by wait times for radiotherapy. In this situation, the alternative treatments would not have been necessary if the patient did not have to wait for radiotherapy (see example scenario v).

**Changing the ready-for-care date**Once a ready-for-care date is set, the only justification for changing it is if one or more of the category A delays described above occur on or before the ready-for-care date. For example, if a patient takes a longer or shorter time than anticipated to heal from pre-radiotherapy surgery, the ready-for-care date may be changed to reflect this. If one or more of these delays happens after the ready-for-care date, the ready-for-care date should remain unchanged. This reflects the fact that had the patient been able to receive radiotherapy as soon as they were ready for care, the second delay would not have occurred. The exception to this rule is where there is a change to either the urgency or intent of treatment; in this case the ready-for-care date should be adjusted to reflect the new clinical assessment of the ready-for-care date.**Example scenarios****Example scenario i:** During a consultation on 18 June, a radiation oncologist recommends radiotherapy and their patient agrees to this treatment. There are no category A delays, meaning that the patient’s ready-for-care date is 18 June. However, there is a wait time of 40 days to start a course of radiotherapy treatment. This is clinically unacceptable to the radiation oncologist, so the patient is prescribed chemotherapy to fill the gap caused by the wait for radiotherapy. However, chemotherapy is not the first choice for treatment and would not have been prescribed if radiotherapy had been available within a clinically acceptable timeframe. Therefore, the patient’s ready-for-care date does not change – it remains 18 June. The period where the patient is having chemotherapy, and the subsequent recovery period, has no bearing on the ready-for-care date. **Example scenario ii:** During a consultation on 9 August, a radiation oncologist recommends radiotherapy and their patient agrees to this treatment. Although the patient is medically ready for treatment, family and work obligations result in the patient requesting a delay of 10 days. The ready-for-care date is therefore 19 August. The service provider has no appropriate timeslots for starting the course of radiotherapy treatment until a further 20 days after the ready-for-care date. The ready-for-care date remains 19 August, with the delay until the start date unrelated, in this case, to the patient’s requested delay.**Example scenario iii:** A clinician determines that a patient requires surgery prior to radiotherapy. The expected recovery time for the surgery is 10 days. The first date after the 10-day healing phase is 30 November, and this date is the patient’s ready-for-care date. This date happens to be a Friday. For this patient, there is a clinical requirement that the first five days of treatment be on consecutive days; however, the service is not open on the weekend, therefore the service cannot offer to start the course of radiotherapy treatment until the following Monday. This is a category B delay, therefore the ready-for-care date should remain the date of 30 November.**Example scenario iv:** A patient is deemed ready for care at a consultation with a radiation oncologist on 23 February. There are no category A delays, therefore the patient’s ready-for-care date is 23 February. If pre-treatment planning and simulation for that patient takes seven days to complete, the ready-for-care date remains 23 February. The ready-for-care date is not moved to seven days later.**Example scenario v:** A radiation oncologist deems a patient will be ready for care on 29 March. Treatment is not available on 29 March and so the start date is planned to be 18 April. On 6 April the patient becomes not ready for care for 20 days (regardless of whether this reason is category A [e.g. treatment for another health condition] or category B [e.g. the patient is sent for other treatment to relieve symptoms while they wait for radiotherapy]). On 26 April the patient becomes ready for care once again. This does not change the ready-for-care date. That is, the time between the ready-for-care date and the start of a course of radiotherapy treatment can include a period where the patient is not ready for care. The rationale for this is that had the patient received radiotherapy treatment on the ready-for-care date (i.e. before the period when the patient became not ready for care), the delay caused by the period of being not ready for care would not have occurred. |

# Appendix 4: Intention of radiotherapy treatment

This data field seeks to capture information on the intent of radiation treatment for a specific course of treatment rather than the overall management of the patient.

Permissible codes to be used with the following definitions:

1 = Prophylactic

2 = Radical

3 = Palliative

4 = Other

5 = Emergency.

## Definitions

Code 1 = Prophylactic

For the purposes of the VRMDS, prophylactic intent is coded when radiotherapy is delivered to a treatment volume that has no history of disease or condition being present at the treatment site but has a high risk of developing based on the current cancer diagnosis.

Inclusion(s):

Prophylactic cranial irradiation e.g. small cell lung cancer or acute lymphoblastic leukaemia.

Code 2 = Radical

Radical or curative radiotherapy is used when treatment is given for the purpose of curing or obtaining permanent control of the disease and includes adjuvant treatment.

Code 3 = Palliative

Palliative radiotherapy is used when cure is unlikely and treatment is given primarily for quality-of-life purposes such as pain control. Other benefits of treatment such as extending life are considered secondary contributions to the patient’s quality of life. In some cases, it is understood palliative radiotherapy may be more complex and is planned to extend life even though a cure is not expected.

Code 4 = Other

This would include treatment of non-malignant disease for controlling symptoms.

List of common non-malignant codes:

E22.0 Acromegaly and pituitary gigantism

E24.9 Cushing’s syndrome, unspecified

G50.0 Trigeminal neuralgia

G50.9 Disorder of trigeminal nerve, unspecified

H06.2 Pain in a joint, ankle and foot

H11.0 Pterygium

H35.3 Degeneration of macula and posterior pole

H93.3 Disorders of acoustic nerve

I47.0 Re-entry ventricular arrhythmia

I47.1 Supraventricular tachycardia

I47.2 Ventricular tachycardia

I47.9 Paroxysmal tachycardia, unspecified

L57.0 Actinic keratosis

L90.5 Scar conditions and fibrosis of skin

L91.0 Hypertrophic scar

M25.7 Osteophyte, multiple sites

M72.0 Palmar fascial fibromatosis [Dupuytren’s]

M72.2 Plantar fascial fibromatosis

Q23.9 Congenital malformation of aortic and mitral valves, unspecified

Q27.3 Peripheral arteriovenous malformation

Q28.0 Arteriovenous malformation of precerebral vessels

Q28.1 Other malformations of precerebral vessels

Q28.2 Arteriovenous malformation of cerebral vessels

T86.0 Bone marrow transplant rejection

Code 5 = Emergency

The treating clinician has assessed the wait time for treatment cannot exceed 24 hours.

# Appendix 5: Treatment technique

## **Permissible codes and definitions of radiation therapy techniques for the Victorian Radiotherapy Minimum Dataset**

Data elements 41, 47, 53 and 59 of the Victorian Radiotherapy Minimum Dataset (VRMDS) seek to capture information on how specialised treatment techniques are used in Victorian public radiation oncology facilities. This list of definitions will help contributing radiation therapy services to define the relevant code for data elements 41, 47, 53 and 59 of the VRMDS and is not intended to fully define the treatment techniques for all clinical applications.

|  |  |
| --- | --- |
| 1 | RT  |
| 3 | IMRT  |
| 5 | SRS includes SABR |
| 5a | SRF (stereotactic radiosurgery frameless) |
| ~~7~~ | ~~Paediatric~~ (Obsolete from 1 July 2023) |
| 9 | TBE  |
| 9a | TBI  |
| 10 | Intracavitary (BRY)  |
| 11 | Intraluminal (BRY)  |
| 12 | Interstitial (BRY)  |
| 13 | Surface applications (BRY)  |
| 14 | Low-dose rate seeds  |
| 15 | SXRT  |
| 16 | DXRT  |
| 17 | VMAT (volumetric modulated arc therapy) |
| 18 | SRT includes SBRT |
| 19 | Gated RT |
| 20 | Adaptive RT  |
| 21 | Intraoperative radiotherapy (IORT) |

Code 1 RT – Radiation therapy

Includes 2D and 3D CRT techniques using photons and/or electrons that cannot be identified as any of the other listed techniques.

For the purposes of VRMDS collection, RT includes megavoltage treatments only.

Code 3 IMRT

Intensity-modulated radiation therapy (IMRT) is a complex method of delivering highly conformal doses of radiation.

For the purposes of VRMDS collection, IMRT is characterised by:

* inverse planning using specialised IMRT software
* modulated dose delivery using physical compensators or automated multileaf collimators (MLCs)
* radiation oncology medical physicists applying quality assurance measures
* the assumption that IGRT is used for delivery.

Code 5 SRS includes SABR

Includes stereotactic radiosurgery (SRS) and stereotactic ablative body radiotherapy (SABR).

Stereotactic radiosurgery (SRS) is a technique used for small target volumes very close to critical structures and requiring a high degree of treatment delivery accuracy.

For the purposes of VRMDS collection, SRS is characterised by:

* a single dose of treatment
* complex planning using specialised stereotactic RT software and complex single-dose treatment delivery using specialised equipment
* radiation oncology medical physicists applying quality assurance measures
* ICD-10M code assisting in defining intracranial/extracranial treatments.

A separate prescription is required for target sites that cannot be treated in a single session due to clinical considerations. Those constitute a separate course.

The following table lists the distinction between stereotactic codes defined in this appendix (see also Code = 18 SRT).

| Target site | Technique description | No. of fractions | VRMDS technique code |
| --- | --- | --- | --- |
| Head (single or multi area) | SRS: Single dose brain treatments where a frame is used | 1 | Code 5 = SRS |
| Head (single or multi area) | SRF: Single dose brain treatments where a frame is not used (mask based) | 1 | Code 5a = SRF |
| Body (single or multi area) | SABR: Single dose body SRS treatments (e.g. true beam) | 1 | Code 5 = SRS  |
| Head (single or multi area) | SRT: Fractionated treatments to the brain | 2+ | Code 18 = SRT |
| Body (single or multi area) | SBRT: Fractionated treatments to the body | 2+ | Code 18 = SRT |

Code 5a SRF (stereotactic radiosurgery frameless)

This technique is a single dose, non-invasive mask-based fixation stereotactic treatment for patients receiving intracranial stereotactic radiosurgery (SRS) for small brain lesions.

This code is not to be used for frame-based treatments (refer to Code 5).

Code 7 Paediatrics – Obsolete from 1 July 2023

The TreatTechnique to be entered for paediatric patients is that which is used to treat the patient as listed in the code list (excluding Code 7).

Includes all patients aged 17 years and under.

Code 9 Total body electrons (TBE)

TBE radiation therapy is used when the treatment target volume is the entire skin surface area and electrons are the radiation type.

For the purposes of VRMDS collection, TBE is characterised by:

* treatment to the entire skin surface using a standing frame and the associated boost fields that are prescribed in a single treatment course
* radiation oncology medical physicists applying quality assurance measures.

Code 9a Total body irradiation (TBI)

TBI radiation therapy is a treatment technique where the x-ray field encompasses the entire body at each fraction and is normally associated with a bone marrow transplant.

For the purposes of VRMDS collection, TBI is characterised by:

* treatment to the entire body, with the patient either lying down or supported to stand
* radiation oncology medical physicists planning and/or applying quality assurance measures.

Code 10 Brachytherapy intracavitary

The insertion of radioactive sources into applicators that are located into body cavities such as the uterus, vagina or nasopharynx.

Code 11 Brachytherapy intraluminal

Use of brachytherapy catheters for vascular insertions. Radiation sources are temporarily inserted into blood vessels.

Code 12 Brachytherapy interstitial

The insertion of devices containing radioactive sources directly into body tissue such as a breast implant.

Excludes low-dose rate prostate seeds (refer to Code 14).

Code 13 Brachytherapy surface applications

Temporary surface application of a radioactive source.

Code 14 Low-dose rate seeds

Permanent implantation of radioactive seeds.

Code 15 SXRT

Superficial x-ray therapy: skin surface treatments utilising beam qualities up to 8 mm Al (beam x-ray energies up to 150 kV) e.g. skin squamous cell carcinoma.

Code 16 DXRT

Deep x-ray therapy: Orthovoltage therapy using beam qualities above 8 mm Al (beam x-ray energies above 150 kV) such as the ribs.

Code 17 VMAT

A dynamic technique characterised by one or more intensity-modulated arcs. Depending on the equipment in use these can be coplanar or no-coplanar arcs, and gantry rotation speed, dose rate and collimator positions can be varied.

Code 18 SRT includes SBRT

Includes stereotactic radiotherapy (SRT) and stereotactic body radiotherapy (SBRT):

1. fractionated treatments
2. all enabled by techniques and technologies that include imaging, beam modulation, dynamic treatment, motion management
3. a high risk associated with relatively large fraction dose, relatively tight margins and dose gradients (highly conformal)
4. intra-fraction motion management where applicable
5. intentionally inhomogeneous dose distributions across the target to maximise dose drop-off and spare surrounding organs at risk
6. often coupled with robust patient immobilisation to improve accuracy of delivery and/or high-precision image-guided delivery.

The following table aims to clarify the distinction between stereotactic codes defined in this appendix (see also Code 5 = SRS).

| Target site | Technique description | No. of fractions | VRMDS technique code |
| --- | --- | --- | --- |
| Head (single or multi area) | SRS: Single dose brain treatments where a frame is used | 1 | Code 5 = SRS |
| Head (single or multi area) | SRF: Single dose brain treatments where a frame is not used (mask based) | 1 | Code 5a = SRF |
| Body (single or multi area) | SABR: Single dose body SRS treatments (e.g. true beam) | 1 | Code 5 = SRS  |
| Head (single or multi area) | SRT: Fractionated treatments to the brain | 2+ | Code 18 = SRT |
| Body (single or multi area) | SBRT: Fractionated treatments to the body | 2+ | Code 18 = SRT |

Code 19 Gated RT

A technique where the radiation beam is turned on and off during delivery to account for target motion. This includes the deep inhalation breath-hold method.

Code 20 Adaptive RT

A technique in which the treatment is re-planned real-time, online to account for internal anatomical changes.

Code 21 Intraoperative radiotherapy

A method of cancer treatment in which a large single dose of radiation is delivered to the tumour or tumour bed via a rigid treatment cone at the time of surgical exposure.

# Appendix 6: Target site code list

| Code and site name | Description |
| --- | --- |
| 01 Eye/orbit | The radiation therapy is directed at the eye and/or orbit. |
| 02 Pituitary | The radiation therapy is directed at the pituitary gland with or without surrounding tissues included. |
| 03 Brain | The radiation therapy is directed at tissues lying within the substance of the brain, or its meninges. |
| 05 Head and neck | The radiation therapy is directed at the oral cavity or oropharyngeal, nasopharyngeal or hypopharyngeal complex with or without regional lymph nodes included. Include all sites that do not fit codes 07–09. |
| 07 Glottis | The radiation therapy is directed at the larynx and/or vocal cords with or without regional nodes included. |
| 08 Sinuses | The radiation therapy is directed at the maxillary or ethmoid sinuses with or without regional nodes included. |
| 09 Parotid | The radiation therapy is directed at the parotid gland with or without regional nodes included. |
| 10 Chest/lung  | The radiation therapy is directed at the lung(s) and/or mediastinum with or without regional lymph nodes included. |
| 12 Oesophagus | The radiation therapy is directed at the oesophagus or gastro-oesophageal junction with or without regional nodes included. |
| 13 Stomach | The radiation therapy is directed at the stomach with or without regional nodes included. |
| 14 Liver | The radiation therapy is directed at the liver with or without regional nodes included. |
| 15 Pancreas | The radiation therapy is directed at the pancreas with or without regional nodes included. |
| 16 Kidney | The radiation therapy is directed at the kidney or kidney bed with or without regional nodes included. |
| 17 Abdomen  | Includes all treatment of abdominal contents that do not fit codes 12–16. |
| 18a Breast (right) | The radiation therapy is directed at the intact RIGHT breast without regional nodes included.  |
| 18b Breast (left) | The radiation therapy is directed at the intact LEFT breast without regional nodes included. |
| 18c Breast (Bilateral) | The radiation therapy that is directed at both breast where the patient has been diagnosed with two primary Sites of Cancer and treated with VMAT. |
| 19a Breast / lymph nodes (right) | The radiation therapy is directed at the intact RIGHT breast with regional nodes included. |
| 19b Breast / lymph nodes (left) | The radiation therapy is directed at the intact LEFT breast with regional nodes included. |
| 19c Breast / lymph nodes (bilateral) | The radiation therapy that is directed at both breast where the patient has been diagnosed with two primary Sites of Cancer and treated with VMAT |
| 20a Chest wall (right) | The radiation therapy is directed at the post-mastectomy RIGHT chest wall without regional nodes included. |
| 20b Chest wall (left) | The radiation therapy is directed at the post-mastectomy LEFT chest wall without regional nodes included. |
| 20c Chest wall (bilateral) | The radiation therapy that is directed at both breast where the patient has been diagnosed with two primary Sites of Cancer and treated with VMAT |
| 21a Chest wall / lymph nodes (right) | The radiation therapy is directed at the post-mastectomy RIGHT chest wall and regional nodes. |
| 21b Chest wall / lymph nodes (left) | The radiation therapy is directed at the post-mastectomy LEFT chest wall and regional nodes. |
| 21c Chest wall / lymph nodes (bilateral) | The radiation therapy that is directed at both breast where the patient has been diagnosed with two primary Sites of Cancer and treated with VMAT |
| 22 Mantle, mini-mantle | The radiation therapy is directed at the lymph nodes above the diaphragm for lymphoma diagnosis patients. |
| 23 Lower extended field | The radiation therapy is directed at the lymph nodes below the diaphragm for lymphoma or seminoma diagnosis patients. |
| 24 Spine | The radiation therapy is directed at the bones of the spine and/or sacrum. |
| 25 Skull | The radiation therapy is directed at the bones of the skull. |
| 26 Ribs | The radiation therapy is directed at the ribs. |
| 27 Hip | The radiation therapy is directed at the bones of the proximal femur and/or hip joint. |
| 28 Pelvic bones | The radiation therapy is directed at the bones of the pelvis. |
| 29 Pelvis | Includes all treatment of pelvic contents that do not fit codes 34, 36, 41, 42, 51. Includes prostatic bed in post-prostatectomy patients. |
| 30 Skin | The radiation therapy is directed at the skin. Excludes skin metastasis, which should be coded 31 (soft tissues). |
| 31 Soft tissue | The radiation therapy is directed at the soft tissue. Includes skin metastasis. |
| 32 Hemi body | A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. |
| 33 Whole body | A single treatment volume encompassing the entire body. |
| 34 Bladder | The radiation therapy is directed at the bladder with or without regional nodes included. |
| 36 Uterus/cervix | The radiation therapy is directed at the uterus and/or cervix with or without regional nodes included. |
| 37 Shoulder | The radiation therapy is directed at the bones of the proximal humerus and/or shoulder joint. |
| 38 Extremity bone, NOS | The radiation therapy is directed at the bones of the extremities including distal portions of femur or humerus. |
| 40 Spinal cord | The radiation therapy is directed at the spinal cord or its meninges. |
| 41 Prostate | The radiation therapy is directed at the prostate without regional nodes included. Use code 29 for post-prostatectomy patients. |
| 42 Prostate / lymph nodes | The radiation therapy is directed at the prostate and regional nodes. Use code 29 for post-prostatectomy patients. |
| 50 Thyroid | The radiation therapy is directed at the thyroid gland with or without regional lymph nodes included. |
| 51 Pelvis GI | The radiation therapy is directed at the colon, rectum or anus with or without regional nodes included. |
| 60 Lymph node region, NOS | The radiation therapy is directed at isolated lymph node regions excluding other targets such as SC nodes and inguinal nodes. |
| 98 Other | The radiation therapy is directed at a region not previously described. |